The BC004 Program is a prospective multicenter clinical study led by Prof. Jiang Huang, the Director of Society of Urology of Chinese Medical Association and the Director of the Department of Urinary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University and AnchorDx with 11 centers participating. This study aims to recruit 1,200 participants. The purpose of this study is to validate the sensitivity and specificity of urine DNA methylation/mutation test in the diagnosis of bladder uroepithelial carcinoma, and to assess its efficacy and clinical application value in China.

This study was officially initiated in March 2020 and enrollment of subjects was completed in December 2021. 

Have completed

ClinicalTrials.gov Identifier: NCT04314245